CORONA Remedies Ltd. Share Price

Corona Remedies Limited ranks among the top 30 pharmaceutical companies in the Indian Pharmaceutical Market (IPM

Stock To Watch

Positives

Stocks to Watch – Market Update

Positives

🧪 Corona Remedies – IPO Listing Overview

Corona Remedies IPO

The Corona Remedies IPO looks like a play for quick listing gains rather than a solid long-term investment opportunity. Primarily focused on women's health and chronic medicines domestically, the company's existing manufacturing is already nearing full capacity. Importantly, this IPO doesn't meaningfully fund new production facilities. With most of the ₹500 crore issue being an Offer for Sale, proceeds largely go to selling shareholders, leaving little for the company's growth-focused capital expenditure – a clear negative for future expansion. While revenue and profit have grown, it's primarily driven by margin improvements and price hikes, not significant volume expansion from new internal capacity. This suggests brand strength over production capability. At roughly 40x PE and 11x PB, the valuation appears rich, especially on a price-to-book basis compared to many domestic peers, even if its India-centric focus offers some appeal. My Opinion: Ultimately, Corona Remedies boasts a strong chronic portfolio and brand, but the lack of capacity expansion and high valuations are concerns. Expect potential 20-30% listing gains, making it a viable short-term trade. For long-term investors seeking compounding growth, however, better opportunities exist.

Corona Remedies IPO — Everything You Need to Know

Pharma company Corona Remedies is coming out with its IPO from December 8 to December 10. The price band is ₹1,008–₹1,062 per share and the IPO size is ₹655.37 crore (Offer For Sale). Since it’s entirely an OFS, no fresh money goes to the company — the existing investors and promoters will sell their shares. Important Dates • Anchor Investors: Dec 5 • Public Issue: Dec 8–10 • Listing: Dec 15 Company Snapshot • Pharma company based in Ahmedabad • Focus areas: Women’s health, diabetes, pain care, cardiology, urology • 67 brands under its portfolio • One of the fastest-growing domestic pharma companies • Reported 16.77% growth CAGR vs industry growth of 9.21% (Jun 2022–Jun 2025) Issue Allocation • QIB: 50% • Retail: 35% • HNI: 10% Why This IPO Looks Attractive • Strong growth in domestic pharma business • Established brand portfolio • Growing focus on women’s healthcare and lifestyle diseases (high demand categories) • Backed by reputed investor ChrysCapital Risks to Consider • OFS issue → company will not receive funds for expansion • Pharma industry faces regulatory challenges and pricing pressure • Market competition is high with many established players Takeaway Corona Remedies is a fast-growing domestic pharma player with strong brands and steady growth. However, since the IPO is 100% OFS, investors should evaluate valuation and listing demand before applying.